FY2024
Effective from
- Inherited rules changed
Primary carnitine deficiency
Billable diagnosis code
CDC/NCHS · FY2024Muscle carnitine palmitoyltransferase deficiency (E71.314)
Ehlers-Danlos syndromes (Q79.6-)
Coverage depends on the payer, service and applicable policy. A billable code does not guarantee payment.
For US diagnosis claims covered by HIPAA, ICD-10-CM is required from October 1, 2015.
Use the service date for outpatient/professional claims and the discharge date for hospital inpatient claims. Earlier encounters use ICD-9-CM; each individual code must also be valid for the applicable date.
Official coding guidelines → · CMS ↗First observed · 2015-10-01
Latest recorded change · FY2024
Effective from
Primary carnitine deficiency
Billable diagnosis code
CDC/NCHS · FY2024| All editions | Effective from | Code history |
|---|---|---|
| FY2016 | 2015-10-01 | First observed |
| FY2017 | 2016-10-01 | No tabular change |
| FY2018 | 2017-10-01 | No tabular change |
| FY2019 | 2018-10-01 | No tabular change |
| FY2020 | 2019-10-01 | Inherited rules changed |
| FY2020 · April | 2020-04-01 | No tabular change |
| FY2021 | 2020-10-01 | Inherited rules changed |
| FY2021 · 01-01 | 2021-01-01 | No tabular change |
| FY2022 | 2021-10-01 | Inherited rules changed |
| FY2022 · 04-01 | 2022-04-01 | No tabular change |
| FY2023 | 2022-10-01 | No tabular change |
| FY2023 · 04-01 | 2023-04-01 | No tabular change |
| FY2024 | 2023-10-01 | Inherited rules changed |
| FY2024 · 04-01 | 2024-04-01 | No tabular change |
| FY2025 | 2024-10-01 | No tabular change |
| FY2025 · 04-01 | 2025-04-01 | No tabular change |
| FY2026 | 2025-10-01 | No tabular change |
| FY2026 · April | 2026-04-01 | No tabular change |
| FY2027 | 2026-10-01 | No tabular change |
Historical mapping only; not an automatic code substitution.
The official Tabular List has no additional instructions at this code level.
Review the instructions inherited from its parent categories below. Inherited instructions ↓
All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Ehlers-Danlos syndromes (Q79.6-)
Muscle carnitine palmitoyltransferase deficiency (E71.314)
Other entries in the same category; these are not automatic substitutes.
| Code | Description | Category · further specificity required |
|---|---|---|
| E71.40 | Disorder of carnitine metabolism, unspecified | Billable / specific |
| E71.42 | Carnitine deficiency due to inborn errors of metabolism | Billable / specific |
| E71.43 | Iatrogenic carnitine deficiency | Billable / specific |
| E71.44 | Other secondary carnitine deficiency | Category · further specificity required |
Official titles and instructions are preserved in their source language. Official sources ↗